Loading stock data…
Lantheus Holdings, Inc. (LNTH)
$100.44-0.53 (-0.52%)
Market ClosedLast close Sep 8
Lantheus Holdings, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lantheus Holdings, Inc. in the Healthcare sector is trading at $100.44 with a market capitalization of $6.6B. Wall Street consensus targets $107.74 (8 analysts), implying a +7.3% move over the next 12 months. The stock is currently near its 52-week high of $111.86, remaining 18.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +7.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $388.18M↑ | $377.33M↓ | $406.79M↑ | $384.01M↑ | $378.05M |
| Gross Profit | $241.85M↑ | $230.92M↓ | $240.88M↑ | $222.37M↓ | $241.01M |
| Operating Income | $100.22M↑ | $81.33M↑ | $77.18M↑ | $43.62M↓ | $87.97M |
| Net Income | $75.03M↓ | $118.42M↑ | $54.09M↑ | $27.77M↓ | $78.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultras...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.59B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.16
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.03
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.99%
Volume
Today's trading volume
1.07M
Recent News
Healthcare Equipment and Supplies Stocks Q2 Recap: Benchmarking Lantheus (NASDAQ:LNTH)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare equipment and supplies industry, including Lantheus (NASDAQ:LNTH) and its peers.
Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 2.7% year on year to $388.2 million. Its non-GAAP profit of $1.55 per share was 18.9% above analysts’ consensus estimates.
1 Healthcare Stock Worth Your Attention and 2 We Question
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 16.6% over the past six months while the S&P 500 was up 7.1%.
Lantheus (LNTH) Agrees To Join Curium In Radiopharmaceuticals Deal
Curium has entered into a definitive agreement to acquire Lantheus Holdings (NasdaqGM:LNTH) in a transaction that will combine their radiopharmaceutical businesses. The deal was unanimously approved by the Lantheus Board and is set to create a larger global player in diagnostic and therapeutic radiopharmaceuticals. The combined group is expected to integrate product portfolios and development pipelines across key imaging and oncology markets. Lantheus Holdings focuses on...
MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading
Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.